StatOrigin open statistical archive
Industries Indicators Regions Rankings Compare Sources

National Medical Products Administration

19 data points extracted from 2 publications by this organisation.

Cite & reuse Official site Get this data as JSON
Data points
19
Documents
2
Indicators
14
Regions
1
Publisher type
Government

Bibliography

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Document Type Published Retrieved Link Data points
Measures facilitate approval of 48 first-in-class innovative drugs Licence: See source Press release — 17 Sep 2026 Reachable 13
China approves 48 innovative drugs in 2024 Licence: See source Press release — 17 Sep 2026 Reachable 6

Every figure

Data points

Every figure taken from this organisation, grouped by indicator.

19 data points across 14 indicators.
IndicatorRegionPeriodValueTypeFull record
Alzheimer's disease innovative drug clinical trial approvals (multi-year total)China2023–20248actual →
Approved innovative drugs designated as breakthrough therapiesChina202413actual →
Approved novel drugs in breakthrough therapy programsChina202413actual →
Cumulative drug approval applications under priority review (annual)China2020–2024496actual →
Drug approval applications completed under priority reviewChina2024110actual →
First-in-class drug approvalsChina202448actual →
First-in-class drug approvalsChina202448actual →
First-in-class drug approvalsChina202340actual →
First-in-class drug approvalsChina202221actual →
Innovative drugs approved via priority review pathwayChina202417actual →
Innovative drugs granted conditional market approvalChina202411actual →
Novel drug approvals via priority review pathwayChina202417actual →
Novel drugs granted conditional market approvalChina202411actual →
Pediatric medicine approvalsChina2024106actual →
Pediatric medicine approvalsChina2024106actual →
Priority review drug approval applications completed growth rateChina202429%actual →
Rare disease medicine approvalsChina202455actual →
Rare disease medicine approvalsChina202455actual →
Share of priority review drug approval applications treating cancer (annual)China2020–202442.5%actual →

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. Credit National Medical Products Administration as the original publisher; each record page carries its own citation.

National Medical Products Administration. Retrieved from StatOrigin: https://statorigin.org/sources/national-medical-products-administration

This organisation as JSON

Keep exploring

Related

Industries using this source

Go further

Last verified 17 September 2026. Link status is rechecked weekly.